Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr;49(4):820-827.
doi: 10.1161/STROKEAHA.117.019653. Epub 2018 Mar 13.

Role of Blood Lipids in the Development of Ischemic Stroke and its Subtypes: A Mendelian Randomization Study

Affiliations

Role of Blood Lipids in the Development of Ischemic Stroke and its Subtypes: A Mendelian Randomization Study

George Hindy et al. Stroke. 2018 Apr.

Abstract

Background and purpose: Statin therapy is associated with a lower risk of ischemic stroke supporting a causal role of low-density lipoprotein (LDL) cholesterol. However, more evidence is needed to answer the question whether LDL cholesterol plays a causal role in ischemic stroke subtypes. In addition, it is unknown whether high-density lipoprotein cholesterol and triglycerides have a causal relationship to ischemic stroke and its subtypes. Our aim was to investigate the causal role of LDL cholesterol, high-density lipoprotein cholesterol, and triglycerides in ischemic stroke and its subtypes through Mendelian randomization (MR).

Methods: Summary data on 185 genome-wide lipids-associated single nucleotide polymorphisms were obtained from the Global Lipids Genetics Consortium and the Stroke Genetics Network for their association with ischemic stroke (n=16 851 cases and 32 473 controls) and its subtypes, including large artery atherosclerosis (n=2410), small artery occlusion (n=3186), and cardioembolic (n=3427) stroke. Inverse-variance-weighted MR was used to obtain the causal estimates. Inverse-variance-weighted multivariable MR, MR-Egger, and sensitivity exclusion of pleiotropic single nucleotide polymorphisms after Steiger filtering and MR-Pleiotropy Residual Sum and Outlier test were used to adjust for pleiotropic bias.

Results: A 1-SD genetically elevated LDL cholesterol was associated with an increased risk of ischemic stroke (odds ratio: 1.12; 95% confidence interval: 1.04-1.20) and large artery atherosclerosis stroke (odds ratio: 1.28; 95% confidence interval: 1.10-1.49) but not with small artery occlusion or cardioembolic stroke in multivariable MR. A 1-SD genetically elevated high-density lipoprotein cholesterol was associated with a decreased risk of small artery occlusion stroke (odds ratio: 0.79; 95% confidence interval: 0.67-0.90) in multivariable MR. MR-Egger indicated no pleiotropic bias, and results did not markedly change after sensitivity exclusion of pleiotropic single nucleotide polymorphisms. Genetically elevated triglycerides did not associate with ischemic stroke or its subtypes.

Conclusions: LDL cholesterol lowering is likely to prevent large artery atherosclerosis but may not prevent small artery occlusion nor cardioembolic strokes. High-density lipoprotein cholesterol elevation may lead to benefits in small artery disease prevention. Finally, triglyceride lowering may not yield benefits in ischemic stroke and its subtypes.

Keywords: cholesterol, HDL; cholesterol, LDL; polymorphism, single nucleotide; stroke; triglycerides.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Association of low-density lipoprotein cholesterol with ischemic stroke and subtypes using different Mendelian randomization (MR) analyses. Odds ratio (OR) of ischemic stroke per 1-SD increase in each lipid trait. Conventional MR estimates were derived from 2-sample MR that forces the intercept of the slope line to zero and does not account for pleiotropy. Multivariable MR adjusts for other lipid traits and MR-Egger adjusts for unbalanced pleiotropy. *Multivariable MR analysis using summary estimates of 343 single nucleotide polymorphisms that adjusts for lipid traits, body mass index (BMI), waist hip ratio adjusted for BMI, fasting plasma glucose, and fasting plasma insulin. CI indicates confidence interval.
Figure 2.
Figure 2.
Association of high-density lipoprotein cholesterol with ischemic stroke and subtypes using different Mendelian randomization (MR) analyses. Odds ratio (OR) of ischemic stroke per 1-SD increase in each lipid trait. Conventional MR estimates were derived from 2-sample MR that forces the intercept of the slope line to zero and does not account for pleiotropy. Multivariable MR adjusts for other lipid traits and MR-Egger adjusts for unbalanced pleiotropy. *Multivariable MR analysis using summary estimates of 343 single nucleotide polymorphisms that adjust for lipid traits, body mass index (BMI), waist hip ratio adjusted for BMI, fasting plasma glucose, and fasting plasma insulin. CI indicates confidence interval.
Figure 3.
Figure 3.
Association of triglycerides with ischemic stroke and subtypes using different Mendelian randomization (MR) analyses. Odds ratio (OR) of ischemic stroke per 1-SD increase in each lipid trait. Conventional MR estimates were derived from 2-sample MR that forces the intercept of the slope line to zero and does not account for pleiotropy. Multivariable MR adjusts for other lipid traits and MR-Egger adjusts for unbalanced pleiotropy. *Multivariable MR analysis using summary estimates of 343 single nucleotide polymorphisms that adjust for lipid traits, body mass index (BMI), waist hip ratio adjusted for BMI, fasting plasma glucose, and fasting plasma insulin. CI indicates confidence interval.

References

    1. Yaghi S, Elkind MS. Lipids and cerebrovascular disease: research and practice. Stroke. 2015;46:3322–3328. doi: 10.1161/STROKEAHA.115.011164. - PMC - PubMed
    1. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. doi: 10.1016/S0140-6736(10)61350-5. - PMC - PubMed
    1. Amarenco P, Bogousslavsky J, Callahan A, 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–559. doi: 10.1056/NEJMoa061894. - PubMed
    1. Hosomi N, Nagai Y, Kohriyama T, Ohtsuki T, Aoki S, Nezu T, et al. J-STARS Collaborators. The Japan Statin Treatment Against Recurrent Stroke (J-STARS): a multicenter, randomized, open-label, parallel-group study. EBioMedicine. 2015;2:1071–1078. doi: 10.1016/j.ebiom.2015.08.006. - PMC - PubMed
    1. Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ. 2014;349:g4379. - PMC - PubMed

Publication types

MeSH terms